A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects with Relapsed/Refractory Multiple Myeloma

Study identifier:D8310C00001

ClinicalTrials.gov identifier:NCT05850234

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase 1b/2 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects with Relapsed/Refractory Multiple Myeloma

Medical condition

Relapsed/ refractory Multiple Myeloma

Phase

Phase 1/2

Healthy volunteers

Study drug

Sex

All

Estimated Enrollment

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 23 Jul 2023

Estimated Primary Completion Date: 16 Dec 2026

Estimated Study Completion Date: 05 Jun 2028

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2024 by AstraZeneca

Collaborators

Inclusion and exclusion criteria

Inclusion Criteria

:
• Males and females ≥18 years of age at the time of consent
• Written informed consent in accordance with federal, local, and institutional guidelines
• Have an ECOG performance status of 0 or 1
• Documented diagnosis of MM per IMWG diagnostic criteria
• Received at least three prior MM treatment lines of therapy
• Have received as part of their previous therapy a PI and IMiD and an antiCD38 antibody.
• Have documented evidence of progressive disease by the IMWG criteria.
• Subjects must have measurable disease at screening, as defined by any of the following: serum monoclonal paraprotein (M-protein) ≥1.0g/dL (10 g/L); urine M-protein ≥200 mg/24 h; serum FLC assay: involved FLC level is ≥10 mg/dL (100 mg/L) and serum kappa lambda FLC ratio is abnormal.
• Adequate bone marrow and organ function assessment at screening according to the hematological, hepatic, and renal parameters listed in the CSP

Exclusion Criteria

:
• Diagnosed or treated for invasive malignancy other than multiple myeloma, except: Malignancy treated with curative intent and with no known active disease present for ≥2 years before enrollment; or
• Adequately treated non-melanoma skin cancer without evidence of disease.
• The following cardiac conditions:
• New York Heart Association (NYHA) stage III or IV congestive heart failure
• Myocardial infarction or coronary artery bypass graft (CABG) ≤6 months prior to enrollment
• History of clinically significant ventricular arrhythmia or unexplained syncope, not believed to be
vasovagal in nature or due to dehydration
• History of severe non-ischemic cardiomyopathy
• Received either of the following:
• An allogenic stem cell transplant within 6 months before apheresis. Subjects who received an
allogeneic transplant must be off all immunosuppressive medications for 6 weeks without signs of
graft-versus-host disease (GVHD).
• An autologous stem cell transplant ≤12 weeks before apheresis
• Known active, or prior history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma.
• Plasma cell leukemia at the time of screening (>2.0×109 /L plasma cells by standard differential), Waldenström's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or primary AL amyloidosis.

Sort by status

No locations available

Arms	Assigned Interventions
Experimental: GC012F (AZD0120) GC012F (AZD0120) will be administrated in one infusion	-

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]